Teriparatide nasal spray: Phase I started

Critical Pharmaceuticals and the University of Nottingham (Nottingham, U.K.) began an open-label, U.K. Phase I trial to compare single doses of 22.5, 45 and 90 µg CP046 vs. 20 µg subcutaneous teripar...